Invitrogen Launches Powerful SAGE(TM) Genomics Technology in Kit Form; Technology Provides Genome-Wide Gene Expression Profiling

Apr 11, 2001, 01:00 ET from Invitrogen Corporation

    SAN DIEGO, April 11 /PRNewswire/ -- Invitrogen Corporation (Nasdaq:   IVGN)
 today announced the availability of a reagent kit to facilitate the use of
 Genzyme Molecular Oncology's SAGE(TM) (Serial Analysis of Gene Expression)
 technology, a novel method that allows a scientist to conduct efficient and
 comprehensive quantitative analyses of all expressed genes in a tissue or cell
 line.  The development of Invitrogen's I-SAGE(TM) research reagent kit is
 expected to significantly increase commercial and academic researchers'
 accessibility to this technology.
     Unlike other expression profiling technologies such as microarrays, SAGE
 is an open system that does not rely on a predetermined collection of genes.
 It can be used in a wide variety of applications such as identifying
 disease-related genes, analyzing the effects of drugs on tissues, and
 providing insight into disease pathways.  Since its introduction, SAGE has
 been used extensively by numerous academic laboratories and commercial
 licensees of SAGE as well as by Genzyme Molecular Oncology, in both its
 internal research programs and on behalf of service customers.
     "SAGE technology is a highly-sensitive tool for genome-wide expression
 profiling," remarked Lyle Turner, Invitrogen's Chairman and CEO.  "By
 providing the SAGE technology in our pre-optimized I-SAGE Kit, Invitrogen will
 make this powerful but complex technology available to academic and commercial
 researchers in a convenient form."
     "Our I-SAGE Kit is a good example of how Invitrogen's products lower the
 technical hurdle associated with complex technologies and processes that are
 used in genetic research.  By introducing I-SAGE, we expect the SAGE
 technology to become more widely adopted," added Mr. Turner.  SAGE users will
 also be able to access the growing public database of SAGE information as well
 as make comparisons with Genzyme Molecular Oncology's proprietary SAGE data,
 which is currently available on Compugen's LabOnWeb Internet site, and which
 will soon be available from Celera Genomics.
     Gail Maderis, President of Genzyme Molecular Oncology commented, "We are
 very pleased to be working with Invitrogen to expand the market for SAGE
 technology.  We expect that the convenience and wide availability of the
 I-SAGE kit will broaden our potential license base for SAGE."
     Invitrogen's I-SAGE Kit can be used in a wide variety of applications such
 as gene discovery, identifying disease-related genes, analyzing the effects of
 drugs on tissues, and providing insight into disease pathways.  Expression
 profiles generated by SAGE are highly quantitative and extremely sensitive for
 low abundance genes, often resulting in the identification of novel genes.
 This makes SAGE a complementary technology for DNA microarray users, helping
 them to identify relevant genes to be arrayed.  Since 1997, more than
 50 publications involving SAGE have been published in leading scientific
 journals.  Recently, a public gene expression database repository for SAGE
 data (SAGEmap) was produced through the National Institute of Health's Cancer
 Genome Anatomy Project (CGAP) and is now capable of accepting submissions of
 SAGE sequence data from any source.  This database currently contains over
 3.9 million SAGE data points and is likely to become an important reference
 database for gene expression analysis, facilitating discovery of novel
 cancer-related genes.
     Commenting on Invitrogen's business arrangements for I-SAGE Kit,
 Mr. Turner stated, "In October 2000, Invitrogen executed an exclusive
 worldwide license from Genzyme Molecular Oncology to sell the SAGE technology
 in standardized reagent kits, and in less than 6 months, we released this new
 product.  Our success in developing the I-SAGE Kit is representative of our
 successful business strategy of licensing technologies from third parties and
 developing convenient laboratory products that bring those technologies into
 widespread use.  We are extremely pleased to be working with Genzyme to
 provide customers with quality products for molecular biology, gene discovery
 and functional genomics research."
 
     About SAGE
     SAGE was developed in the laboratory of Drs. Bert Vogelstein and Ken
 Kinzler at Johns Hopkins University, Baltimore.  A U.S. Patent for SAGE was
 issued in 1997.  Genzyme has an exclusive license for commercial applications
 of SAGE and offers sublicenses to commercial users of the I-SAGE kit.
 
     About Invitrogen
     Invitrogen Corporation develops, manufactures and markets research tools
 in kit form and provides other research products and services to biotechnology
 and biopharmaceutical researchers and companies worldwide.  The company
 manufactures and markets thousands of products and services that simplify and
 improve gene cloning, gene expression, and gene analysis techniques for
 corporate, academic and government entities.  The company also engages in
 technology licensing, research services, large-scale production, and life
 science technical expertise and support.  Founded in 1987, Invitrogen is
 headquartered in San Diego, California and has operations in more than
 20 countries and distributor relationships in 40 more.  The company employs
 approximately 3,000 people at its worldwide locations.
 
     About Genzyme Molecular Oncology
     Genzyme Molecular Oncology is positioned where the power and promise of
 genomics and biotechnology meet.  It is utilizing its powerful proprietary
 functional genomics and antigen discovery technology platforms to develop
 novel cancer products focused on cancer vaccines and angiogenesis inhibitors,
 and to generate partnering revenues.  It is shaping these new therapies
 through the integration of its genomics, gene and cell therapy, small-molecule
 drug discovery, and protein therapeutic capabilities.  Genzyme Molecular
 Oncology is a division of Genzyme Corp.  SAGE is a trademark of Genzyme
 Corporation, and Genzyme is a registered trademark and service mark of Genzyme
 Corporation.
 
     Certain statements contained in this press release are considered
 "forward-looking statements" within the meaning of the Private Securities
 Litigation Reform Act of 1995, and it is Invitrogen's intent that such
 statements be protected by the safe harbor created thereby.  Such statements
 include, but are not limited to, statements concerning 1) the success of
 I-SAGE(TM) in increasing the accessibility of SAGE(TM) technology to
 researchers and whether I-SAGE(TM) results in SAGE(TM) becomes more widely
 adopted; 2) the success of I-SAGE(TM) in identifying new or novel genes;
 3) the availability of SAGE(TM) data from Celera Genomics; and 4) whether the
 I-SAGE(TM) kit will broaden the licensee base for SAGE(TM) technology.  Such
 forward-looking statements are subject to a number of risks, uncertainties and
 other factors that could cause actual results to differ materially from future
 results expressed or implied by such forward-looking statements.  Potential
 risks and uncertainties include, but are not limited to:  a) whether
 Invitrogen's marketing, sales and other efforts to promote the I-SAGE(TM) Kit
 will succeed sufficiently to increase the adoption of SAGE(TM) technology and
 the number of licensees of that technology; b) whether the users of I-SAGE(TM)
 will apply the technology to applications having the potential to identify new
 genes; c) the efforts of Celera Genomics to launch its SAGE(TM) database
 offering; and d) whether the technology is sufficiently sensitive in those
 applications to identify new genes, and other factors beyond the companies'
 direct control, in addition to competition and other risks and uncertainties
 detailed from time to time in the Securities and Exchange Commission filings
 of Invitrogen and Genzyme Corporation.
 
 

SOURCE Invitrogen Corporation
    SAN DIEGO, April 11 /PRNewswire/ -- Invitrogen Corporation (Nasdaq:   IVGN)
 today announced the availability of a reagent kit to facilitate the use of
 Genzyme Molecular Oncology's SAGE(TM) (Serial Analysis of Gene Expression)
 technology, a novel method that allows a scientist to conduct efficient and
 comprehensive quantitative analyses of all expressed genes in a tissue or cell
 line.  The development of Invitrogen's I-SAGE(TM) research reagent kit is
 expected to significantly increase commercial and academic researchers'
 accessibility to this technology.
     Unlike other expression profiling technologies such as microarrays, SAGE
 is an open system that does not rely on a predetermined collection of genes.
 It can be used in a wide variety of applications such as identifying
 disease-related genes, analyzing the effects of drugs on tissues, and
 providing insight into disease pathways.  Since its introduction, SAGE has
 been used extensively by numerous academic laboratories and commercial
 licensees of SAGE as well as by Genzyme Molecular Oncology, in both its
 internal research programs and on behalf of service customers.
     "SAGE technology is a highly-sensitive tool for genome-wide expression
 profiling," remarked Lyle Turner, Invitrogen's Chairman and CEO.  "By
 providing the SAGE technology in our pre-optimized I-SAGE Kit, Invitrogen will
 make this powerful but complex technology available to academic and commercial
 researchers in a convenient form."
     "Our I-SAGE Kit is a good example of how Invitrogen's products lower the
 technical hurdle associated with complex technologies and processes that are
 used in genetic research.  By introducing I-SAGE, we expect the SAGE
 technology to become more widely adopted," added Mr. Turner.  SAGE users will
 also be able to access the growing public database of SAGE information as well
 as make comparisons with Genzyme Molecular Oncology's proprietary SAGE data,
 which is currently available on Compugen's LabOnWeb Internet site, and which
 will soon be available from Celera Genomics.
     Gail Maderis, President of Genzyme Molecular Oncology commented, "We are
 very pleased to be working with Invitrogen to expand the market for SAGE
 technology.  We expect that the convenience and wide availability of the
 I-SAGE kit will broaden our potential license base for SAGE."
     Invitrogen's I-SAGE Kit can be used in a wide variety of applications such
 as gene discovery, identifying disease-related genes, analyzing the effects of
 drugs on tissues, and providing insight into disease pathways.  Expression
 profiles generated by SAGE are highly quantitative and extremely sensitive for
 low abundance genes, often resulting in the identification of novel genes.
 This makes SAGE a complementary technology for DNA microarray users, helping
 them to identify relevant genes to be arrayed.  Since 1997, more than
 50 publications involving SAGE have been published in leading scientific
 journals.  Recently, a public gene expression database repository for SAGE
 data (SAGEmap) was produced through the National Institute of Health's Cancer
 Genome Anatomy Project (CGAP) and is now capable of accepting submissions of
 SAGE sequence data from any source.  This database currently contains over
 3.9 million SAGE data points and is likely to become an important reference
 database for gene expression analysis, facilitating discovery of novel
 cancer-related genes.
     Commenting on Invitrogen's business arrangements for I-SAGE Kit,
 Mr. Turner stated, "In October 2000, Invitrogen executed an exclusive
 worldwide license from Genzyme Molecular Oncology to sell the SAGE technology
 in standardized reagent kits, and in less than 6 months, we released this new
 product.  Our success in developing the I-SAGE Kit is representative of our
 successful business strategy of licensing technologies from third parties and
 developing convenient laboratory products that bring those technologies into
 widespread use.  We are extremely pleased to be working with Genzyme to
 provide customers with quality products for molecular biology, gene discovery
 and functional genomics research."
 
     About SAGE
     SAGE was developed in the laboratory of Drs. Bert Vogelstein and Ken
 Kinzler at Johns Hopkins University, Baltimore.  A U.S. Patent for SAGE was
 issued in 1997.  Genzyme has an exclusive license for commercial applications
 of SAGE and offers sublicenses to commercial users of the I-SAGE kit.
 
     About Invitrogen
     Invitrogen Corporation develops, manufactures and markets research tools
 in kit form and provides other research products and services to biotechnology
 and biopharmaceutical researchers and companies worldwide.  The company
 manufactures and markets thousands of products and services that simplify and
 improve gene cloning, gene expression, and gene analysis techniques for
 corporate, academic and government entities.  The company also engages in
 technology licensing, research services, large-scale production, and life
 science technical expertise and support.  Founded in 1987, Invitrogen is
 headquartered in San Diego, California and has operations in more than
 20 countries and distributor relationships in 40 more.  The company employs
 approximately 3,000 people at its worldwide locations.
 
     About Genzyme Molecular Oncology
     Genzyme Molecular Oncology is positioned where the power and promise of
 genomics and biotechnology meet.  It is utilizing its powerful proprietary
 functional genomics and antigen discovery technology platforms to develop
 novel cancer products focused on cancer vaccines and angiogenesis inhibitors,
 and to generate partnering revenues.  It is shaping these new therapies
 through the integration of its genomics, gene and cell therapy, small-molecule
 drug discovery, and protein therapeutic capabilities.  Genzyme Molecular
 Oncology is a division of Genzyme Corp.  SAGE is a trademark of Genzyme
 Corporation, and Genzyme is a registered trademark and service mark of Genzyme
 Corporation.
 
     Certain statements contained in this press release are considered
 "forward-looking statements" within the meaning of the Private Securities
 Litigation Reform Act of 1995, and it is Invitrogen's intent that such
 statements be protected by the safe harbor created thereby.  Such statements
 include, but are not limited to, statements concerning 1) the success of
 I-SAGE(TM) in increasing the accessibility of SAGE(TM) technology to
 researchers and whether I-SAGE(TM) results in SAGE(TM) becomes more widely
 adopted; 2) the success of I-SAGE(TM) in identifying new or novel genes;
 3) the availability of SAGE(TM) data from Celera Genomics; and 4) whether the
 I-SAGE(TM) kit will broaden the licensee base for SAGE(TM) technology.  Such
 forward-looking statements are subject to a number of risks, uncertainties and
 other factors that could cause actual results to differ materially from future
 results expressed or implied by such forward-looking statements.  Potential
 risks and uncertainties include, but are not limited to:  a) whether
 Invitrogen's marketing, sales and other efforts to promote the I-SAGE(TM) Kit
 will succeed sufficiently to increase the adoption of SAGE(TM) technology and
 the number of licensees of that technology; b) whether the users of I-SAGE(TM)
 will apply the technology to applications having the potential to identify new
 genes; c) the efforts of Celera Genomics to launch its SAGE(TM) database
 offering; and d) whether the technology is sufficiently sensitive in those
 applications to identify new genes, and other factors beyond the companies'
 direct control, in addition to competition and other risks and uncertainties
 detailed from time to time in the Securities and Exchange Commission filings
 of Invitrogen and Genzyme Corporation.
 
 SOURCE  Invitrogen Corporation